scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
77 hedge funds and large institutions have $121M invested in scPharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 11 closing their positions.
1,392% more call options, than puts
Call options by funds: $388K | Put options by funds: $26K
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
2.99% more ownership
Funds ownership: 74.17% → 77.16% (+3%)
1% more funds holding
Funds holding: 76 → 77 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
10% less capital invested
Capital invested by funds: $134M → $121M (-$13.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$3.3M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.55M |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$950K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$696K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$506K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$1.09M |
| 2 |
Walleye Capital
New York
|
-$799K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$431K |
| 4 |
Millennium Management
New York
|
-$259K |
| 5 |
Squarepoint
New York
|
-$188K |
SCPH Hedge Fund Activity: Q2 2024 in Review
77 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q2 2024, worth a combined $121M — down 9.8% from $134M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new SCPH positions and 11 closed out — a net gain of 1 holder — while 30 added to existing stakes and 23 trimmed.
The largest buyer was Luther King Capital Management (LKCM), adding an estimated $3.3M. The largest seller was J. Goldman & Co, cutting an estimated $1.09M.
- 77 institutional investors held scPharmaceuticals (SCPH) as of Q2 2024, up from 76 in Q1 2024.
- Funds reported $121M of scPharmaceuticals stock for Q2 2024, down 9.8% quarter-over-quarter.
- 12 funds opened new scPharmaceuticals positions in Q2 2024 and 11 closed out, a net change of +1 holder.
- The largest scPharmaceuticals buyer in Q2 2024 was Luther King Capital Management (LKCM), an estimated $3.3M added.
- The largest scPharmaceuticals seller in Q2 2024 was J. Goldman & Co, an estimated $1.09M sold.
Based on aggregated 13F filings for Q2 2024.